Your browser doesn't support javascript.
loading
In silico approaches in organ toxicity hazard assessment: current status and future needs in predicting liver toxicity.
Bassan, Arianna; Alves, Vinicius M; Amberg, Alexander; Anger, Lennart T; Auerbach, Scott; Beilke, Lisa; Bender, Andreas; Cronin, Mark T D; Cross, Kevin P; Hsieh, Jui-Hua; Greene, Nigel; Kemper, Raymond; Kim, Marlene T; Mumtaz, Moiz; Noeske, Tobias; Pavan, Manuela; Pletz, Julia; Russo, Daniel P; Sabnis, Yogesh; Schaefer, Markus; Szabo, David T; Valentin, Jean-Pierre; Wichard, Joerg; Williams, Dominic; Woolley, David; Zwickl, Craig; Myatt, Glenn J.
Afiliação
  • Bassan A; Innovatune srl, Via Giulio Zanon 130/D, 35129 Padova, Italy.
  • Alves VM; The National Institute of Environmental Health Sciences, Division of the National Toxicology, Program, Research Triangle Park, NC 27709, USA.
  • Amberg A; Sanofi, R&D Preclinical Safety Frankfurt, Industriepark Hoechst, D-65926 Frankfurt am Main, Germany.
  • Anger LT; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
  • Auerbach S; The National Institute of Environmental Health Sciences, Division of the National Toxicology, Program, Research Triangle Park, NC 27709, USA.
  • Beilke L; Toxicology Solutions Inc., San Diego, CA, USA.
  • Bender A; AI and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
  • Cronin MTD; Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW.
  • Cross KP; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK.
  • Hsieh JH; Instem, 1393 Dublin Road, Columbus, OH 43215. USA.
  • Greene N; The National Institute of Environmental Health Sciences, Division of the National Toxicology, Program, Research Triangle Park, NC 27709, USA.
  • Kemper R; Data Science and AI, DSM, IMED Biotech Unit, AstraZeneca, Boston, USA.
  • Kim MT; Nuvalent, One Broadway, 14th floor, Cambridge, MA, 02142, USA.
  • Mumtaz M; US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, 20993, USA.
  • Noeske T; Office of the Associate Director for Science (OADS), Agency for Toxic Substances and Disease, Registry, US Department of Health and Human Services, Atlanta, GA, USA.
  • Pavan M; Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Pletz J; Innovatune srl, Via Giulio Zanon 130/D, 35129 Padova, Italy.
  • Russo DP; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK.
  • Sabnis Y; Department of Chemistry, Rutgers University, Camden, NJ 08102, USA.
  • Schaefer M; The Rutgers Center for Computational and Integrative Biology, Camden, NJ 08102, USA.
  • Szabo DT; UCB Biopharma SRL, Chemin du Foriest - B-1420 Braine-l'Alleud, Belgium.
  • Valentin JP; Sanofi, R&D Preclinical Safety Frankfurt, Industriepark Hoechst, D-65926 Frankfurt am Main, Germany.
  • Wichard J; PPG Industries, Pittsburgh, PA 15146, USA.
  • Williams D; UCB Biopharma SRL, Chemin du Foriest - B-1420 Braine-l'Alleud, Belgium.
  • Woolley D; Bayer AG, Genetic Toxicology, Müllerstr. 178, 13353 Berlin, Germany.
  • Zwickl C; Functional & Mechanistic Safety, Clinical Pharmacology & Safety Sciences, AstraZeneca, Darwin Building 310, Cambridge Science Park, Milton Rd, Cambridge CB4 0FZ, UK.
  • Myatt GJ; ForthTox Limited, PO Box 13550, Linlithgow, EH49 7YU, UK.
Comput Toxicol ; 202021 Nov.
Article em En | MEDLINE | ID: mdl-35340402
ABSTRACT
Hepatotoxicity is one of the most frequently observed adverse effects resulting from exposure to a xenobiotic. For example, in pharmaceutical research and development it is one of the major reasons for drug withdrawals, clinical failures, and discontinuation of drug candidates. The development of faster and cheaper methods to assess hepatotoxicity that are both more sustainable and more informative is critically needed. The biological mechanisms and processes underpinning hepatotoxicity are summarized and experimental approaches to support the prediction of hepatotoxicity are described, including toxicokinetic considerations. The paper describes the increasingly important role of in silico approaches and highlights challenges to the adoption of these methods including the lack of a commonly agreed upon protocol for performing such an assessment and the need for in silico solutions that take dose into consideration. A proposed framework for the integration of in silico and experimental information is provided along with a case study describing how computational methods have been used to successfully respond to a regulatory question concerning non-genotoxic impurities in chemically synthesized pharmaceuticals.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article